Trials / Active Not Recruiting
Active Not RecruitingNCT02362503
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 371 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-663068 | BMS-663068 |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2015-02-23
- Primary completion
- 2016-08-18
- Completion
- 2026-09-30
- First posted
- 2015-02-13
- Last updated
- 2025-08-22
- Results posted
- 2018-09-18
Locations
139 sites across 25 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, South Africa, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02362503. Inclusion in this directory is not an endorsement.